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Abstract
Background: Varenicline is an effective smoking cessation medication. Some concern has been raised that its use
may precipitate adverse cardiovascular events although no patho-physiological mechanism potentially underlying
such an effect has been reported. The aim of this study was to test the hypothesis that varenicline impacts on
sympatho-vagal balance during smoking withdrawal.
Methods: In this randomised, placebo-controlled trial, muscle sympathetic nerve activity (MSNA), baroreflex
sensitivity (BRS), heart rate, and blood pressure were assessed in 17 smokers four weeks before a quit attempt
(baseline) and again on the third day of that quit attempt (acute smoking withdrawal).
Results: Regarding the primary endpoint of our study, we did not find a significant effect of varenicline compared
to placebo on changes in MSNA burst incidence between baseline and acute smoking withdrawal (−3.0 ± 3.3
vs.−3.9 ± 5.0 bursts/100 heart beats; p = 0.308). However, heart rate and systolic blood pressure significantly decreased
in the placebo group only, while no significant changes in these parameters were observed in the varenicline group.
Exposure to smoking cues during acute withdrawal lead to a significant increase of heart rate in the placebo group,
while heart rate decreased in the varenicline group, and the difference in these changes was significant between
groups (+2.7 ± 1.0 vs.−1.8 ± 0.5 1/min; p = 0.002). In all 17 participants combined, a significant increase in heart rate
during smoking cue exposure was detected in subjects who relapsed in the course of six weeks after the quit date
compared to those who stayed abstinent (+2.5 ± 1.2 vs.−1.1 ± 0.7; p = 0.018). Six-week abstinence rates were higher in
the varenicline group compared to placebo (88 vs. 22 % p = 0.015).
Conclusion: We did not find evidence of adverse effects of varenicline on sympatho-vagal balance. Varenicline
probably blunts the heart rate response to smoking cues, which may be linked to improved cessation outcome.
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Background
Among all first-line smoking cessation drugs currently
available, varenicline is particularly effective: In a recent
network meta-analysis, it was found to produce higher
abstinence rates than placebo, bupropion, or single
forms of nicotine replacement therapy [1]. Despite one
large randomised trial showing no increased risk of
cardiovascular events in smokers taking varenicline
compared to placebo [2], a meta-analysis of 14 trials
published before March 2011 concluded that varenicline
use was associated with a 1.06 % risk of adverse cardio-
vascular events while this risk was only 0.82 % in pa-
tients taking placebo, and this difference was significant
[3]. So far, no plausible pathophysiological mechanism
underlying this effect has been suggested.
Research of the past two decades has identified distur-
bances of the autonomic nervous system as key mecha-
nisms involved in the pathophysiology of cardiovascular
diseases including heart failure [4], coronary heart dis-
ease [5], and hypertension [6, 7]. In these conditions, a
shift of sympatho-vagal balance towards increased sym-
pathetic activity has been observed. This may play a
major role in promoting disease progression: In patients
suffering from heart failure, increased sympathetic activ-
ity is directly linked to worse clinical outcome [8].
In 1998, Narkiewicz and colleagues demonstrated that
acute smoking elicited a significant increase in sympa-
thetic activity [9]. In addition, smoking reduces vagal
modulation of the sinuatrial node [10–12] and baroreflex
gain [13], thus further contributing to sympatho-vagal
imbalance. Given the link between sympatho-vagal im-
balance and cardiovascular morbidity and mortality,
some of the health benefits of quitting smoking may be
attributable to decreased sympathetic activity and im-
proved vagal function following smoking cessation. In
fact, increased heart rate variability (indicative of im-
proved vagal function) has recently been documented
even after only three days of abstinence [14]. This sug-
gests that sympathetic activity is probably reduced dur-
ing acute smoking withdrawal; however, we are not
aware of any studies assessing sympathetic activity dur-
ing withdrawal.
So far, the effects of varenicline on sympathetic and
vagal activity have not been investigated. As nicotinic
acetylcholine receptors are involved in signal transduction
within the sympathetic nervous system, the partial recep-
tor agonist varenicline may induce sympatho-excitation,
thereby offsetting some of the beneficial effects of smok-
ing cessation on sympatho-vagal balance. At the same
time, the acute stress reaction associated with cravings
(e.g. upon exposure to smoking cues [15, 16]) might be
blunted in the presence of varenicline due to its partially
agonistic action that is believed to relieve craving. More-
over, therapeutic doses of varenicline desensitize the
nicotine receptor. Receptor desensitization may also play
a role in blunting the stress response associated with crav-
ings, and may attenuate the impact of inhaled nicotine
during smoking relapse [17].
The first aim of this study was to investigate the effect
of varenicline on sympatho-vagal balance during smok-
ing withdrawal. We hypothesised that acute (48–72 h)
smoking withdrawal elicits a decrease in sympathetic ac-
tivity and that varenicline attenuates this effect.
Our second aim was to investigate the effect of vareni-
cline on changes in sympatho-vagal balance elicited by
exposure to smoking cues during acute smoking with-
drawal. We hypothesised that varenicline would impact
on sympatho-vagal balance during smoking cue expos-
ure, and that the direction and magnitude of changes
elicited by smoking cues would be related to short-term
cessation rates.
Methods
The study was registered with BfArM, the European
Clinical Trials Database (EudraCT No. 2011-000843-26),
and clinicaltrials.gov (NCT01474265) and approved by
the Ethics Committee of Göttingen University (Applica-
tion number 29/4/11). At the screening visit, eligibility of
the subjects was assessed and written informed consent
obtained.
Male and female smokers aged between 25 and 60 years
and displaying at least moderate nicotine dependence (≥5
points on the Fagerström Test of Nicotine Dependence;
FTND [18]) were invited to participate in the study. Preg-
nant women and subjects suffering from diseases known
to increase sympathetic activity (e.g., heart failure, COPD,
depression, obstructive sleep apnoea, pulmonary-arterial
hypertension) or taking drugs impacting on sympatho-
vagal balance (e.g., beta blockers, selective serotonin re-
uptake inhibitors, theophylline) were excluded.
Study outline
The timeline of the study is displayed in Fig. 1. At the
baseline visit, a smoking history was taken, and baseline
sympatho-vagal balance was measured as described
below. Following the baseline visit, participants were
randomised to either the varenicline or the placebo
group. All subjects received professional smoking ces-
sation support in a six-week group programme with
proven effectiveness [19]. Each of the weekly sessions
lasted 90–120 min, with a maximum of 12 participants
per group. During the first sessions, medical and psycho-
logical issues were discussed, and participants were
asked to observe their own smoking behaviour. During
the remainder of the course, coping skills and relapse
prevention were addressed.
Participants were asked to set their target quit date
(TQD) between the second and the third course session
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and instructed to start using their study medication eight
days before their TQD. Study medication was up-
titrated as previously described for varenicline [20]. A
second evaluation of sympatho-vagal balance was sched-
uled for day 2 of the quit attempt (follow up I) as
withdrawal symptoms tend to peak around 2–3 days
after the quit date [21]. Short-term continuous abstin-
ence was assessed during a third visit six weeks after the
TQD (follow up II). Abstinence at both follow up points
was biochemically validated (exhaled carbon monoxide
(CO) concentration of < 6 ppm). Subjects failing to pro-
vide a CO reading were assumed to be smoking.
Experimental protocol
The same experimental protocol was used for both
assessments of sympatho-vagal balance (baseline &
follow up I). Smokers had to abstain from cigarette
smoking 1 h before baseline. Subjects were in a supine
position. First, continuous recordings of heart rate and
blood pressure (non-invasive beat-to-beat analysis using
the Portapres device; FMS®, Amsterdam, Netherlands)
were established.
After mapping the course of the peroneal nerve around
the head of the fibula by transcutaneous electrical stimula-
tion (Stimuplex HNS 11, B Braun, Melsungen, Germany),
a tungsten microelectrode (shaft diameter 200 μm and tip
of 1–5 μm, FHC, Bowdoin, ME, USA) was inserted into
the nerve. Nerve signals were amplified (~100,000 times),
filtered (band width of 700–2000 Hz), and processed by a
resistance-capacitance integrating network with a time
constant of 0.1 s, providing a mean voltage display of
muscle sympathetic nerve activity (MSNA) (Nerve Traffic
Analysis System, model 662C-3, University of Iowa, Iowa
City, USA). The procedure and the criteria for obtaining a
satisfactory recording of MSNA have been described pre-
viously [22].
At baseline, MSNA, blood pressure and heart rate were
continuously recorded for 20 min at rest. At follow up I,
recordings under resting conditions were repeated, and
following that, participants were exposed to a smoking
cue: They were allowed to touch a pack of their favourite
cigarette brand and their lighter for two minutes.
Data analysis
Two minutes of raw data were collected for each of the
two conditions (rest and smoking cue exposure). MSNA
was assessed by quantifying grouped single fibre activity.
These ‘bursts’ of sympathetic activity were identified by
inspection of the mean voltage neurogram, and the
number of bursts observed during the two-minute
period were reported as burst frequency (bursts/min) or
as burst incidence (bursts/100 heart beats). Baroreflex
sensitivity (BRS), reflecting vagal activity, was calculated
using the sequence method [23]. Briefly, recordings of
continuous systolic blood pressure measurements were
analyzed for sequences of ≥ 4 consecutive beats with
progressive increase or decrease in blood pressure and a
linearly related change in the pulse interval (correlation
coefficient r ≥ 0.85). BRS (ms/mmHg) was identified as
the slope of the regression line between pulse interval
and blood pressure change within each sequence.
Statistical analyses were performed with SPSS Statistics
21 (IBM Corporation, New York, USA). The primary end-
point was the between-group difference in changes in
MSNA burst incidence (bursts/100 heart beats) between
baseline and follow up I. These were assessed by a re-
peated measures ANOVA. Within-group changes were
assessed by paired T tests. Between-group differences at
baseline were analysed by unpaired T tests. Abstinence
rates in the placebo and the varenicline group were com-
pared using Fisher’s exact test. Data are presented as
mean ± SEM (continuous variables), as appropriate. Sig-
nificance levels were set to 0.05.
Based on the results obtained in a previous study [24],
complete MSNA data from 12 participants were needed
in order to detect a change by 7 bursts/100 heart beats
on an alpha level of 5 with 80 % power. In order to ac-
count for drop-outs due to limited MSNA signal quality
(30 % of cases), a total of 17 subjects had to be enrolled
in each group.
Varenicline
Placebo
Screening:
- informed consent
- smoking history
- FTND
TQD – 5 weeks
Baseline:
- tobacco use
- exhaled CO
- MSNA
TQD – 4 weeks
TQD 
Follow-up I:
- tobacco use
- exhaled CO
- MSNA 
+ smoking cue
Varenicline treatment for 12 weeks (includes up-titration 8 days prior to TQD)
Placebo treatment for 12 weeks (pills identical to varenicline) 
Follow-up II:
- tobacco use
- exhaled CO
TQD + 6 weeksTQD + 2days 
Fig. 1 Study timeline
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Results
A total of 36 Caucasian smokers were enrolled in the
study, but 12 were excluded due to early relapse (eight
in the placebo and four in the varenicline group). An-
other seven subjects were excluded from the analysis
due to the fact that an MSNA signal could not be
obtained on both baseline and follow up I to assess the
primary endpoint (two in the placebo and five in the
varenicline group). Subjects that failed to provide a CO
reading (three at follow up I; two at follow up II) were
assumed to be smoking.
Table 1 presents baseline characteristics of those 17
subjects that were included in the analysis. These sub-
jects had stopped smoking on their target quit date and
remained continuously abstinent until follow up I. With
an average FTND score of 6.8 ± 0.4 points in the overall
group, participants were moderately dependent. There
were no significant differences between the groups with
regard to baseline characteristics (Table 1).
Changes in parameters between baseline and follow up
I are displayed in Table 2. Regarding the primary end-
point of our study, changes in MSNA burst incidence
(bursts/100 heart beats) did not differ between groups.
During smoking withdrawal, MSNA as expressed in
burst frequency (bursts/min), as well as heart rate and
systolic blood pressure, significantly decreased in the
placebo group only, as assessed by paired T tests. In the
varenicline group there were no significant changes
during smoking withdrawal. As groups were compared,
no significant group differences in changes were found.
The significant decrease in MSNA burst frequency, heart
rate and systolic blood pressure, which was observed in
the placebo group, was accompanied by a tendential
increase in BRS.
Changes in parameters between resting conditions at
follow up I and exposure to smoking cues at follow up I
are displayed in Table 3. There were no significant
changes in MSNA, BRS, or blood pressure within groups
and changes did not differ between groups for these
parameters. Heart rate significantly increased during
smoking cues in the placebo group. In contrast, heart rate
significantly decreased in the varenicline group. The dif-
ference of these changes between groups was significant.
Two out of nine subjects in the placebo and seven out
of eight subjects in the varenicline group remained con-
tinuously abstinent over a period of six weeks after the
quit date (22 vs. 88 %; p = 0.015). Table 4 displays the
association between changes in parameters during
Table 1 Subject characteristics at baseline
Placebo Varenicline p (independent
T test)n = 9 n = 8
Female gender 56 % (5) 50 % (4) 0.488
Age [years] 42.4 ± 3.6 44.5 ± 3.8 0.699
Height [cm] 174.0 ± 2.1 176.1 ± 4.1 0.641
Weight [kg] 82.8 ± 4.8 83.1 ± 4.8 0.960
Body Mass Index [kg/m2] 27.3 ± 1.4 26.8 ± 0.9 0.775
Number of cigarettes
smoked per day
22.3 ± 2.4 26.9 ± 1.7 0.151
Age at onset of smoking 15.4 ± 0.5 14.6 ± 0.4 0.220
Pack Years 24.1 ± 3.4 37.9 ± 6.3 0.066
number of previous
quit attempts
3.6 ± 1.5 3.1 ± 1.2 0.840
FTND score 6.3 ± 0.5 7.4 ± 0.5 0.162
MSNA burst frequency
[bursts/min]
37.8 ± 5.3 37.4 ± 2.8 0.950
MSNA burst incidence
[bursts/100 heart beats]
58.1 ± 7.1 56.9 ± 4.6 0.890
Heart rate [1/min] 63.8 ± 2.4 66.4 ± 3.3 0.529
BRS [ms/mmHg] 15.8 ± 6.9 9.4 ± 2.5 0.454
SBP [mmHg] 136.4 ± 4.1 130.8 ± 4.3 0.354
DBP [mmHg] 80.6 ± 2.6 83.3 ± 2.7 0.481
Table 2 Changes (Δ) of parameters at rest between baseline
and acute smoking withdrawal (follow up I)
Parameters Δ (follow up I - baseline) p value for
interaction
(repeated
measures
ANOVA)
Placebo Varenicline
MSNA burst frequency
[bursts/min]
−6.3 ± 2.4* −2.7 ± 2.4 0.308
MSNA burst incidence
[bursts/100 heart beats]
−3.0 ± 3.3 −3.9 ± 5.0 0.886
Heart rate [1/min] −6.9 ± 2.6* −0.5 ± 2.1 0.078
BRS [ms/mmHg] +6.6 ± 3.4 −2.3 ± 2.9 0.086
SBP [mmHg] −8.4 ± 3.4* −3.4 ± 2.5 0.277
DBP [mmHg] −3.4 ± 2.3 +0.4 ± 3.3 0.333
*p < 0.05 for within-group changes assessed in a paired T test
Table 3 Changes (Δ) of parameters during acute withdrawal
(follow up I) between rest and smoking cue exposure
Parameters Δ (smoking cues – rest) p value for
interaction
(repeated
measures
ANOVA)
Placebo Varenicline
MSNA burst frequency
[bursts/min]
−0.7 ± 1.4 +0.3 ± 2.4 0.747
MSNA burst incidence
[bursts/100 heart beats]
−3.5 ± 2.5 +1.6 ± 3.6 0.262
Heart rate [1/min] +2.7 ± 1.0* −1.8 ± 0.5* 0.002
BRS [ms/mmHg] −3.7 ± 2.0 +11.4 ± 7.5 0.061
SBP [mmHg] +2.3 ± 2.6 +4.0 ± 2.4 0.639
DBP [mmHg] +2.5 ± 1.7 −1.5 ± 2.9 0.228
*p < 0.05 for within-group changes assessed in a paired T test
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exposure to smoking cues and smoking abstinence or re-
lapse. The overall group was divided into two subgroups
of subjects that were continuously abstinent and those
who relapsed. No significant between-group differences
in pre-post changes were observed for MSNA, BRS, or
blood pressure. In subjects who remained abstinent,
heart rate decreased during cue exposure, while it in-
creased in subjects who went on to relapse. While both
within-group changes were non-significant, a repeated-
measures ANOVA revealed a significant interaction be-
tween group and cue exposure.
Discussion
We conducted a randomised trial comparing the effects
of varenicline and placebo on sympatho-vagal balance
and cue reactivity during acute smoking withdrawal.
Regarding the primary endpoint of our study, we did not
find a significant effect of varenicline versus placebo on
changes in sympathetic activity as expressed in MSNA
burst incidence between baseline and acute smoking
withdrawal.
To our knowledge, this is the first study to measure
MSNA during acute smoking withdrawal. We found a
significant decrease in heart rate accompanied by a
decrease in MSNA burst frequency during withdrawal in
subjects treated with placebo only (Table 2). These find-
ings are in line with earlier findings of decreased sympa-
thetic activity [25] and increased vagal activity [14, 26]
following smoking cessation. Likewise, our data corrob-
orate previous reports of a significant decrease in heart
rate and systolic blood pressure during withdrawal [27].
Numerous studies have reported a decrease in resting
heart rate during acute withdrawal [28], and one
common explanation for this finding is that nicotine
stimulates norepinephrine release [29] and might even
have direct effects on cardiac tissue [30]. Given that
significant changes in heart rate, systolic blood pressure
and burst frequency were only found in the placebo
group, we assume that varenicline might have blunted
the mechanisms underlying these effects due to its par-
tially agonistic action at nicotine receptors.
Regarding the second aim of our study, we assessed
the effect of varenicline on smoking cue reactivity during
withdrawal (Table 3). We detected a significant effect of
varenicline on the heart rate response towards smoking
cues. While heart rate increased in the placebo group, it
decreased in the varenicline group. There was a tenden-
tial difference (p = 0.061) between groups regarding the
change in BRS, which leaves open the question, if these
changes in heart rate were regulated by changes in BRS.
With regards to continuous smoking abstinence over
the course of six weeks after the quit date, we found a
significant difference in the heart rate response towards
smoking cues between subjects that remained abstinent
and those who went on to relapse (Table 4). A larger in-
crease in heart rate following cue exposure was noted in
subjects who relapsed. As discussed above, varenicline
might have blunted the increase in heart rate or even re-
duced the heart rate in response to smoking cues. This
might be a result of partial nicotine receptor agonism
and/or receptor desensitisation elicited by varenicline.
Relieving craving and blunting the stress response
towards smoking cues might be one of the reasons why var-
enicline is an effective smoking cessation agent. Our study
supports this assumption on a pathophysiological level.
The association between cue-induced changes in heart
rate and subsequent quitting success has not been stud-
ied in great detail, and the available studies took differ-
ent experimental approaches than the one used in the
present trial [31, 32]. If our findings are replicated in ad-
equately powered trials, assessment of cue-induced heart
rate changes during withdrawal might be introduced as
a simple tool to predict the likelihood of relapse. Given
that heart rate can be modulated by simple interventions
such as slow breathing [24], this approach might then
even pave the way for new interventions fostering ab-
stinence on the subconscious level [33].
Strengths and limitations
The results presented here were derived from a
randomised-controlled trial using sophisticated experi-
mental methods. In addition to being highly reprodu-
cible, MSNA measurements provide a clearer and more
consistent reflection of acute and chronic changes in
sympathetic activity than other measures of sympathetic
activity [34–37]. Smoking status was biochemically vali-
dated, and we took a conservative approach by treating
all subjects with missing data on their smoking status as
smokers [38]. Interpretation of our findings is limited by
the fact that subgroup analyses involved small samples.
Table 4 Association between changes (Δ) in parameters following
exposure to smoking cues during withdrawal (follow up I) and
continuous abstinence at follow up II (six weeks after the target
quit date)
Parameters Δ (smoking cues – rest) p value for
interaction
(repeated
measures
ANOVA)
Continuous abstinence
(n = 9)
Relapse
(n = 8)
MSNA burst frequency
[bursts/min]
+0.5 ± 2.1 −1.1 ± 1.6 0.554
MSNA burst incidence
[bursts/100 heart beats]
+1.4 ± 3.2 −4.0 ± 2.8 0.237
Heart rate [1/min] −1.1 ± 0.7 +2.5 ± 1.2 0.018
BRS [ms/mmHg] +9.3 ± 6.6 −3.8 ± 2.3 0.107
SBP [mmHg] +4.5 ± 2.2 +1.0 ± 2.9 0.342
DBP [mmHg] +0.4 ± 2.5 +1.3 ± 2.0 0.779
Haarmann et al. Tobacco Induced Diseases  (2016) 14:26 Page 5 of 7
We failed to detect a significant effect on the primary
endpoint of the study, and as the power calculation was
based on a sample size of 12 in both groups, the study
was slightly underpowered. Finally, we did not assess re-
activity to neutral cues that are unrelated to smoking. As
recent research suggests that cue-induced changes in
some measures of vagal tone only occur following smok-
ing cues (as opposed to neutral cues) [39], future studies
assessing sympatho-vagal tone during withdrawal should
also include neutral cues.
Conclusions
This study does not suggest any adverse effects of vare-
nicline on sympatho-vagal balance, which is in line with
recent reviews that affirmed cardiovascular safety of var-
enicline [40–43]. Varenicline probably blunts the heart
rate response to smoking cues, which may be linked to
improved cessation outcome.
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